PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV.
about
Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug TherapyIncidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis.Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction.Landscape review of current HIV 'kick and kill' cure research - some kicking, not enough killing.Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.Immune checkpoint inhibitors in challenging populations.Durable complete response to nivolumab in a patient with HIV and metastatic non-small cell lung cancer.Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy.Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer.Systemic Treatment of Metastatic Conjunctival Melanoma.Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling.Immune Checkpoint Inhibitors in Melanoma and HIV Infection.CD4+ T Cell Differentiation in Chronic Viral Infections: The Tfh Perspective.An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients.Immune Checkpoints as the Immune System Regulators and Potential Biomarkers in HIV-1 InfectionAnti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?Drug response to PD-1/PD-L1 blockade: based on biomarkersTargeting Immune Checkpoint Molecules to Eliminate Latent HIVCheckpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations
P2860
Q28073100-0D496E4F-C4D5-42D9-9263-9EDBC9E4C461Q37306007-05F31D6B-985F-4368-B199-CEF776E8D8B4Q37346118-0416739A-0EDD-4518-A23A-E50A67F41F12Q38636019-47BA5925-121A-441D-BF5F-C60FC08961EEQ38930084-7B84DCA3-D832-40D3-9141-FD3888C4EDAAQ38939708-0E3CFE42-394D-44CF-A469-8824F6B786AAQ40109733-CCFFE4C3-4B9E-42EC-BB49-8EB1BC01B18DQ40148689-F2938839-61A7-4CF8-90B6-7F4D67623BEAQ42369857-CC91CF93-9213-4401-ABE4-237724D1C417Q47108077-DAB24F93-DE36-4ABA-8987-F902A24DCBE2Q47125276-6059A34A-DC3A-4993-95BB-8BA8EDCD8182Q47138765-39D963C0-F615-46B2-B840-757D70CD3922Q47580241-D0F90AE7-5FBA-4D16-9582-C16DEFFEC282Q55450663-C3C572F3-503E-4EA9-9625-A43DC9BAD75DQ56891188-34BD3D19-AC1B-41FD-96BA-0809F59B5565Q56893675-12CBBEB1-3A0F-4AFE-AC15-C31893F6F819Q58795673-CB12208E-C6D5-4D0D-B089-C3C569881E1DQ59127701-B5006D23-026E-42C0-B649-0A933C221098Q59135661-D3D421C0-C250-46F6-9293-DAD81FDF7FDE
P2860
PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV.
@ast
PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV.
@en
type
label
PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV.
@ast
PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV.
@en
prefLabel
PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV.
@ast
PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV.
@en
P2093
P2860
P356
P1476
PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV.
@en
P2093
Chelsea Pruckner
Diwakar Davar
John M Kirkwood
Melissa Wilson
P2860
P304
P356
10.1155/2015/737389
P577
2015-09-10T00:00:00Z